Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

• Histologically proven cancer.
• Written informed consent.
• Age >/= 18 years.
• Life expectancy of at least 12 weeks.
• World Health Organization (WHO) performance status of 0 or 1.
• Adequate Hematological and biochemical indices to support investigational therapy.
• All women of childbearing potential (WOCBP) must have a negative serum pregnancy test.
• WOCBP and fertile men and their partners must agree to use an effective form of contraception during the study and for 90 days after the last dose of study medication.
• Measurable and evaluable disease.
• All toxic manifestations of previous treatment must have resolved.
• Able to undergo MRI scanning.

Exclusion Criteria:

• Radiotherapy, endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosureas and Mitomycin-C) prior to treatment.
• Pregnant and lactating women.
• Major thoracic and/or abdominal surgery in the preceding four weeks from which the patient has not yet recovered.
• Patients which have active uncontrolled infections.
• Patients with any other condition that in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
• Patients known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
• Previous or ongoing cardiac conditions.
• Uncontrolled hypertension.
• Patients taking any drug known to prolong the QTc interval.
• Patients who have had any ischaemic or vascular damage from previous radiotherapy.
• Patients taking warfarin or heparin.
• Patients taking naproxen.
• Patients taking supplements or multivitamins containing vitamin C.
• Patients should not be taking any other investigational drug for the duration of the study.
• Patients with brain metastases or neurological tissue involvement of the spinal column.